CenExel is proud to highlight the poster presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Annual Scientific Meeting, February 2023, Washington,...
Our Clinical Sciences team, comprised of Dr. Larry Ereshefsky, Dr. Brett English, Dr. Robert Litman, along with Principal Investigators Dr. Djouher Hough, and Dr. Haig...
CenExel is proud to highlight the poster presented at the Annual CNS Summit, November 2022, Boca Raton, FL. ABSTRACT Introduction: Placebo and nocebo responses continue...
General medicine studies are not immune to the placebo effect, where 30-40% of patients report improved subjective and objective outcomes in general medical studies (Hrobjartsson &...
Characterizing human abuse potential liability can be dependent on many factors, including pharmacology, pharmacokinetics, and the intended population. We can help.
Salt Lake City, June 16, 2022 /GlobeNewswire/ — CenExel announces the acquisition of Apex Innovative Sciences, parent company of Collaborative Neuroscience Research (CNS) and Hassman...
CenExel is proud to highlight the poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP), May 2022, Scottsdale, AZ. ABSTRACT...
CenExel is proud to highlight the poster presented at the Schizophrenia International Research Society (SIRS) Annual Scientific Meeting, April 2022, Florence Italy. ABSTRACT Background: Clinical...
CenExel is proud to highlight the poster presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Annual Scientific Meeting, February 2022, Washington,...
